Adverse Remodeling and Reverse Remodeling After Myocardial Infarction
Ankeet S Bhatt1, Andrew P Ambrosy2,3, Eric J Velazquez4,5
1Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Current Cardiology Reports
|June 30, 2017
Summary
This review summarizes post-myocardial infarction (MI) cardiac remodeling, focusing on heart failure and left ventricular changes. Current treatments aim to prevent adverse remodeling and improve outcomes, with ongoing research into new therapeutic pathways.
Area of Science:
- Cardiology
- Cardiac Physiology
- Translational Medicine
Background:
- Post-myocardial infarction (MI) heart failure prevalence is increasing due to longer patient survival.
- Left ventricular (LV) changes after MI involve complex cellular, extracellular, and neurohormonal interactions.
Purpose of the Study:
- To review current literature on cardiac remodeling following myocardial infarction.
- To cover pathophysiological mechanisms, imaging, treatments, and future research directions.
Main Methods:
- Literature review of studies on post-myocardial infarction remodeling.
- Analysis of pathophysiological considerations, imaging modalities, and treatment strategies.
Main Results:
- Adverse LV remodeling, defined by enlarged LV cavity or reduced ejection fraction, correlates with poor clinical outcomes.
- Neurohormonal regulation plays a key role in adverse cardiac remodeling, guiding current therapeutic strategies.
Conclusions:
- Current treatments like revascularization, neurohormonal blockade, and device therapies aim to prevent adverse remodeling and promote reverse remodeling.
- Further research into novel mechanisms of adverse LV remodeling is needed to enhance current evidence-based therapies.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:21Myocarditis I: Introduction
493
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
493
01:29Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
655
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
655
01:14Myocarditis III: Medical Management
266
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
568
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
568